Welcome > Support > Âü°íÀÚ·á  
 
 
E
 
±Ûº¸±â
¼º¸í ÆÄ³ªÁø     (Date : 2016-07-13 10:14:42)
Á¦¸ñ [³í¹®] [2013]Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase In
³»¿ë

Korean J Pathol. 2013 Feb;47(1):52-60. doi: 10.4132/KoreanJPathol.2013.47.1.52. Epub 2013 Feb 25.

Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase Inhibitor Treatment.

Lee HJ1Xu XKim HJin YSun PKim JEChung JH.

Author information

Abstract

BACKGROUND:

The aims of this study were to evaluate the abilities of direct sequencing (DS), peptide nucleic acid (PNA) clamping, and pyrosequencing methods to detect epidermal growth factor receptor (EGFR) mutations in formalin-fixed paraffin-embedded (FFPE) non-small cell lung carcinoma (NSCLC) samples and to correlate EGFR mutational status as determined by each method with the clinical response to EGFR tyrosine kinase inhibitors (TKIs).

METHODS:

Sixty-one NSCLC patients treated with EGFR TKIs were identified to investigate somatic mutations in the EGFR gene (exons 18-21).

RESULTS:

Mutations in the EGFR gene were detected in 38 of the 61 patients (62%) by DS, 35 (57%) by PNA clamping and 37 (61%) by pyrosequencing. A total of 44 mutations (72%) were found by at least one of the three methods, and the concordances among the results were relatively high (82-85%; kappa coefficient, 0.713 to 0.736). There were 15 discordant cases (25%) among the three different methods.

CONCLUSIONS:

All three EGFR mutation tests had good concordance rates (over 82%) for FFPE samples. These results suggest that if the DNA quality and enrichment of tumor cells are assured, then DS, PNA clamping, and pyrosequencing are appropriate methods for the detection of EGFR mutations.



 

 ¹øÈ£   Á¦¸ñ ÀÛ¼ºÀÚ ÆÄÀÏ Á¶È¸
   49           [³í¹®] [2016]Comparison of EGFR .. ÆÄ³ªÁø 30584
   48           [³í¹®] [2015]IDH Mutation Analys.. ÆÄ³ªÁø 65535
   47           [³í¹®] [2015]Low frequency of KR.. ÆÄ³ªÁø 34019
   46           [³í¹®] [2015]Simultaneous genoty.. ÆÄ³ªÁø 6373
   45           [³í¹®] [2014]Simultaneous diagno.. ÆÄ³ªÁø 23998
   44           [³í¹®] [2014]KRAS Mutation Detec.. ÆÄ³ªÁø 11170
   43           [³í¹®] [2013]Detection of EGFR m.. ÆÄ³ªÁø 1403
   42           [³í¹®] [2013]Detection and compa.. ÆÄ³ªÁø 6040
   41           [³í¹®] [2013]Detection of BRAF V.. ÆÄ³ªÁø 6373
¢º           [³í¹®] [2013]Comparison of Direc.. ÆÄ³ªÁø 29291
   39           [³í¹®] [Microarray]Peptide nucle.. ÆÄ³ªÁø 14582
   38           [³í¹®] [Clamp]Rapid and Sensitiv.. ÆÄ³ªÁø 34539
   37           [³í¹®] [ÆÄ³ªÁø Á¦Ç°»ç¿ë ³í¹®] EGFR µ¹¿¬º¯.. ÆÄ³ªÁø 3646
   36           [³í¹®] [ÆÄ³ªÁø Á¦Ç°»ç¿ë ³í¹®] Development .. ÆÄ³ªÁø 17297
   35           [³í¹®] [ÆÄ³ªÁø Á¦Ç°»ç¿ë ³í¹®] JHDM3A modul.. ÆÄ³ªÁø 1430
   34           [³í¹®] [PNA Chip vs DNA Chip ÀÓ»ó.. ÆÄ³ªÁø 7527
   33           [³í¹®] [ÆÄ³ªÁø ³í¹®¹ßÇ¥] PNA-mediated Re.. ÆÄ³ªÁø 14743
   32           [³í¹®] [ÆÄ³ªÁø Á¦Ç°»ç¿ë ³í¹®] ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡.. ÆÄ³ªÁø 18412
   31           [³í¹®] [ÆÄ³ªÁø ³í¹® ¹ßÇ¥] PNA-Based Anti.. ÆÄ³ªÁø 1441
   30           [³í¹®] [ÆÄ³ªÁø ³í¹®¹ßÇ¥]Peptide nucleic .. ÆÄ³ªÁø 4179
 

< 1 2 3 >